Hypoxia‐inducible factor 1α (HIF‐1α) correlated with tumor growth and apoptosis in ovarian cancer

The aims of this study were to investigate the hypoxia-inducible factor 1α (HIF-1α) protein inhibition and tumor growth by a molecular target of rapamycin inhibitor, rapamycin, in xenogeneic transplant model of ovarian cancer and to study the correlation of apoptosis with HIF-1α and vascular endothelial growth factor (VEGF) expression. Four groups of female nude mice were inoculated subcutaneous with SKOV-3 cells and treated with vehicle, rapamycin, paclitaxel, or rapamycin plus paclitaxel. The expressions of HIF-1α and VEGF and microvessel density (MVD) were assessed by immunohistochemistry. While messenger RNA (mRNA) expression of Glut1, bcl-2, and VEGF was studied by reverse transcription–polymerase chain reaction, and apoptosis of tumor cells was determined by terminal deoxynucleotidyl biotin-dUTP nick end labeling (TUNEL). The HIF-1α was expressed in epithelial ovarian cancer. There was a significant correlation between HIF-1α protein expression and VEGF or MVD. Tumor burden treated with rapamycin alone, rapamycin plus paclitaxel, and paclitaxel alone was reduced (47.91%, 51.03%, and 31.75%, respectively) compared with controls. The expression of HIF-1α was inhibited, and apoptotic index of tumor cell increased in rapamycin and rapamycin plus paclitaxel group. HIF-1α may upregulate VEGF expression both in mRNA and protein level. There is a positive correlation between HIF-1α and MVD. Rapamycin inhibits expression of HIF-1α and suppresses ovarian tumor growth. Our data suggested that a combination of HIF-1α inhibitor and chemotherapy could provide an effective approach for inhibiting tumor growth in ovarian cancer.

[1]  W. Murdoch.  OVARIAN SURFACE EPITHELIUM, OVULATION AND CARCINOGENESIS , 1996, Biological reviews of the Cambridge Philosophical Society.

[2]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[3]  H. Friess,et al.  Hypoxia-Inducible Factor 1 Regulates Vascular Endothelial Growth Factor Expression in Human Pancreatic Cancer , 2003, Pancreas.

[4]  D. Mottet,et al.  CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.

[5]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[6]  W. Friedrichs,et al.  Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. , 2002, Cancer research.

[7]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[8]  S. Capaccioli,et al.  Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase , 2001, Oncogene.

[9]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[10]  A. Harris,et al.  Hypoxia‐inducible factor‐1α in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways , 2004, International journal of cancer.

[11]  G. Mills,et al.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.

[12]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[13]  T. Nikaido,et al.  Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. , 2002, Anticancer research.

[14]  J. M. Arbeit,et al.  Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .

[15]  M. Volm,et al.  Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. , 2000, Anticancer research.

[16]  G. Mills,et al.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.

[17]  M. Schindl,et al.  Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Xianglin Shi,et al.  Vanadate-induced Expression of Hypoxia-inducible Factor 1α and Vascular Endothelial Growth Factor through Phosphatidylinositol 3-Kinase/Akt Pathway and Reactive Oxygen Species* , 2002, The Journal of Biological Chemistry.

[19]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[20]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[21]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.